NRD
PTCT icon

Nebula Research & Development’s PTC Therapeutics PTCT Stock Holding History

Nebula Research & Development’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-9,492
Closed -$428K – 1110
2024
Q4 		$428K Buy
+9,492
New +$406K 0.05% 612
2023
Q4 		– Sell
-21,858
Closed -$490K – 839
2023
Q3 		$490K Buy
+21,858
New +$813K 0.26% 133

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nebula Research & Development's PTCT Position: Q1 2025 in Review

Nebula Research & Development sold out of PTC Therapeutics (PTCT) in Q1 2025, closing a stake of 9,492 shares — an estimated $428K sold.

Nebula Research & Development first reported a position in PTCT in Q3 2023 and held it in 2 quarters. The position peaked at $490K in Q3 2023. 260 funds tracked by Wall St. Rank hold PTCT as of Q1 2025.

  • Nebula Research & Development reported no remaining PTC Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Nebula Research & Development sold 9,492 PTC Therapeutics shares in Q1 2025, an estimated $428K.
  • Nebula Research & Development first reported a position in PTC Therapeutics in Q3 2023 and held it in 2 quarters.
  • Nebula Research & Development's PTC Therapeutics position peaked at $490K in Q3 2023.
  • 260 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2025.

Based on Nebula Research & Development's 13F filing for Q1 2025, filed 15 May 2025.